# Efficacy and Safety of L19TNF in Previously Treated Patients with Advanced Stage or Metastatic Soft-tissue Sarcoma

> **NCT04733183** · PHASE2 · ACTIVE_NOT_RECRUITING · sponsor: **Philogen S.p.A.** · enrollment: 98 (estimated)

## Conditions studied

- Soft Tissue Sarcoma

## Interventions

- **DRUG:** Dacarbazine
- **DRUG:** onfekafusp alfa

## Key facts

- **NCT ID:** NCT04733183
- **Lead sponsor:** Philogen S.p.A.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2020-08-28
- **Primary completion:** 2025-12
- **Final completion:** 2025-12
- **Target enrollment:** 98 (ESTIMATED)
- **Last updated:** 2025-01-27


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04733183

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04733183, "Efficacy and Safety of L19TNF in Previously Treated Patients with Advanced Stage or Metastatic Soft-tissue Sarcoma". Retrieved via AI Analytics 2026-05-25 from https://api.ai-analytics.org/clinical/NCT04733183. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*